Hennion & Walsh Asset Management Inc. Decreases Holdings in MorphoSys AG (NASDAQ:MOR)

Hennion & Walsh Asset Management Inc. lowered its holdings in MorphoSys AG (NASDAQ:MOR) by 1.0% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 123,310 shares of the company’s stock after selling 1,235 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in MorphoSys were worth $2,338,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Carlson Capital L P purchased a new stake in MorphoSys in the first quarter valued at $17,241,000. Susquehanna International Group Ltd. acquired a new stake in shares of MorphoSys during the first quarter worth about $1,333,000. Henry James International Management Inc. lifted its holdings in shares of MorphoSys by 105.8% in the 1st quarter. Henry James International Management Inc. now owns 88,506 shares of the company’s stock valued at $1,605,000 after purchasing an additional 45,506 shares during the last quarter. SAL Trading LLC acquired a new stake in shares of MorphoSys in the 1st quarter valued at about $486,000. Finally, BNP Paribas Financial Markets grew its stake in MorphoSys by 130.4% during the 1st quarter. BNP Paribas Financial Markets now owns 32,533 shares of the company’s stock worth $590,000 after buying an additional 18,413 shares during the last quarter. Institutional investors and hedge funds own 18.38% of the company’s stock.

MorphoSys Stock Performance

MOR opened at $18.96 on Friday. The firm has a market cap of $2.86 billion, a price-to-earnings ratio of -5.45 and a beta of 1.20. MorphoSys AG has a 52 week low of $4.18 and a 52 week high of $19.50. The business’s 50 day moving average is $18.96 and its two-hundred day moving average is $18.57. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 4.98.

MorphoSys Company Profile

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity.